MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, held its Annual and Extraordinary General Meeting of shareholders in Zaventem today. The shareholders approved all agenda items of the Annual General Meeting, including the financial statements for the financial year ended 31 December 2011.
The quorum requirement for deliberation and voting on the agenda items of the Extraordinary General Meeting was not met. A second Extraordinary General Meeting will be held on Friday 15 June 2012 at 10:00 AM at the Airport Meeting Center, Brussels Airport, Box 75, 1930 Zaventem, Belgium, or at such place as will be indicated at that place at that time.
MDxHealth (mdxhealth.com) is a leading molecular diagnostics company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. Follow us on Twitter at: twitter.com/mdxhealth.
For more information:
Mike Sinclair, Halsin Partners
T: +44(0)20 7318 2955 / C: +44(0)79 6802 2075 -
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.